Skip to main content

Uterine Cancer Drugs Market is Expected to Gain Popularity Across the Globe by 2028

 


Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.

Uterine Cancer Drugs Market Drivers

Increasing funding for cancer research, rising insurance coverage, and increasing number of new targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size. For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Uterine Cancer Drugs Market - Regional Analysis

Geographically, uterine cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above.

 

Comments

Popular posts from this blog

The Global Autoclave Equipment Market Continues To Grow Owing To the Rising Demand from Healthcare Sectors for Sterilizing Medical Equipment to Ensure the Safety of the Post-Surgical Period

  Autoclave equipment is the most popular sterilization method in the industry and is used for many applications including the manufacture of food products. It is widely used in the foodservice industry to sterilize and cleanse equipment used in the process of preparing and serving food. The autoclave is the abbreviated form of autolysis which means oxidation. Autoclaves have various parts including an electric motor, a condenser, and a burner. Autoclave equipment includes vials for sealing the autoclave, a glass or plastic container that has been lined with wax or plastic, and the appropriate autoclave equipment accessories such thermometer for measuring the temperature of the autoclave. All modern steam sterilizing equipment & autoclave machines provide a much-refined workflow experience, which makes you reconsider whether or not steam sterilizing is all it can be. A wide range of sterilization methods is used for sterilizing your medical and laboratory specimen so the right ...

Biologics Market Increasing Prevalence of Chronic Diseases to Augment Growth of the market

  A  biologic  drug ( biologics ) is a product that is produced from living organisms or contains components of living organisms.  Biologic  drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Market Dynamics In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologicsmarket . 

Treprostinil Drugs Market - High Prevalence of Pulmonary Arterial Hypertension and R&D of New Formulations of Treprostinil to Augment Growth of market

  Treprostinil is an antihypertensive agent used to treat patients with pulmonary arterial hypertension. It can also be used in the treatment of Degos disease, an extremely rare disorder in which small and medium sized arteries become blocked (occlusive arteriopathy), restricting the flow of blood to affected areas. Market Dynamics High prevalence of pulmonary arterial hypertension is expected to propel growth of the treprostinil drugs market . For instance, according to the study, ‘High Geographic Prevalence of Pulmonary Artery Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published in February 2020, in the journal Pulmonary Circulation, the overall pulmonary arterial hypertension incidence was 14 cases per million and the annual period prevalence of pulmonary arterial hypertension was 93 cases per million. Decline in new prescriptions for treprostinil-based products is expected to hinder growth of the treprostinil drugs market. For instance, United The...